

**Universe Pharmaceuticals INC (the “Company”)**

**PROXY FOR 2023 ANNUAL MEETING OF SHAREHOLDERS**

The undersigned shareholder of the Company, hereby acknowledges receipt of the Notice of Annual General Meeting of shareholders (the “Meeting”) and the Proxy Statement, each dated May 24, 2023, and hereby appoints \_\_\_\_\_ of \_\_\_\_\_ or, if no person is otherwise specified, the chairman of the Meeting, as proxy, with full power of substitution, on behalf and in the name of the undersigned, to represent the undersigned at the Meeting of the Company to be held on July 3, 2023, at 10:00 a.m., Beijing time, at 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji’an City, Jiangxi 343100, the People’s Republic of China, and to vote all ordinary shares which the undersigned would be entitled to vote if then and there personally present, on the matters set forth below (i) as specified by the undersigned below and, (ii) in the discretion of any proxy, upon such other business as may properly come before the Meeting, as set forth in the Notice of the Meeting and in the Proxy Statement furnished herewith.

**This proxy when properly executed will be voted in the manner directed herein by the undersigned shareholder. If no direction is made, this proxy will be voted FOR the proposals.**

**July 3, 2023**

**THE BOARD RECOMMENDS A VOTE FOR  
ALL THE PROPOSALS.**

**I. As an ordinary resolution, that Gang Lai be re-elected as a director of the Company to hold office until the next annual general meeting of the Company**

FOR                       AGAINST                       ABSTAIN

**II. As an ordinary resolution, that Lin Yang be re-elected as a director of the Company to hold office until the next annual general meeting of the Company**

FOR                       AGAINST                       ABSTAIN

**III. As an ordinary resolution, that Jiawen Pang be re-elected as a director of the Company to hold office until the next annual general meeting of the Company**

FOR                       AGAINST                       ABSTAIN

**IV. As an ordinary resolution, that Ding Zheng be re-elected as a director of the Company to hold office until the next annual general meeting of the Company**

FOR                       AGAINST                       ABSTAIN

**V. As an ordinary resolution, that Yongping Yu be re-elected as a director of the Company to hold office until the next annual general meeting of the Company**

FOR                       AGAINST                       ABSTAIN

**VI. As an ordinary resolution, that the Company’s authorized share capital, be increased effective immediately, from US\$312,500 divided into 90,000,000 ordinary shares of US\$0.003125 par value each and 10,000,000 preferred shares of US\$0.003125 par value each, to US\$3,125,000 divided into 900,000,000 ordinary shares of par value \$0.003125 per share and 100,000,000 preferred shares of par value \$0.003125 per share**

FOR                       AGAINST                       ABSTAIN

**VII. As a special resolution, subject to approval by the shareholders of Proposal No. 6 (the Increase of Share Capital), the Company adopt a third amended and restated memorandum of association to reference the increased authorized share capital (in the form set out in Annex A of the accompanying proxy statement), in substitution for and to the exclusion of, the memorandum of association of the Company currently in effect**

FOR                       AGAINST                       ABSTAIN

**VIII. As ordinary resolutions, that:**

- 1. conditional upon the approval of the Board of Directors in its sole discretion, with effect as of the date the Board of Directors of the Company may determine:**
  - a. the authorized, issued and outstanding shares of the Company (collectively, the “Shares”) be consolidated by consolidating each 10 Shares of the Company, or such lesser whole share amount as the Board of Directors may determine in its sole discretion, such amount not to be less than 2, into 1 Share of the Company, with such consolidated Shares having the same rights and being subject to the same restrictions (save as to nominal value) as the existing Shares of par value US\$0.003125 each in the capital of the Company as set out in the Company’s articles of association (the “Share Consolidation”);**
  - b. no fractional Shares be issued in connection with the Share Consolidation and, in the event that a shareholder would otherwise be entitled to receive a fractional Share upon the Share Consolidation, the number of Shares to be received by such shareholder be rounded up to the next highest whole number of Shares; and**
  - c. any change to the Company’s authorized share capital in connection with, and as necessary to effect, the Share Consolidation be and is hereby approved, such amendment to be determined by the Board of Directors in its sole discretion; and**
- 2. any one director or officer of the Company be and is hereby authorized, for and on behalf of the Company, to do all such other acts or things necessary or desirable to implement, carry out and give effect to the Share Consolidation, if and when deemed advisable by the Board of Directors in its sole discretion”)**

FOR                       AGAINST                       ABSTAIN

**IX. As a special resolution that, subject to approval by the shareholders of Proposal No. 8 (the Share Consolidation), and entirely conditional upon the effectiveness of the Share Consolidation, with effect as of the date the Company’s board of directors may determine in its sole discretion, the Company adopt a fourth amended and restated memorandum of association to reflect the Share Consolidation, in substitution for and to the exclusion of, the memorandum of association of the Company in effect immediately prior to effectiveness of the Share Consolidation**

FOR                       AGAINST                       ABSTAIN

This Proxy is solicited on behalf of the management of Universe Pharmaceuticals INC. This Proxy, when properly executed, will be voted in the manner directed herein by the undersigned shareholder. If no direction is made, this Proxy will be voted FOR the proposals described above.

**TO VOTE ONLINE:** www.transhare.com click on Vote Your Proxy  
Enter Your Control Number:

**TO VOTE BY EMAIL:** Anna Kotlova at akotlova@bizsolaconsulting.com

**TO VOTE BY FAX:** Please fax this proxy card to 1.727. 269.5616

**TO VOTE BY MAIL:** Please sign, date and mail to

**Anna Kotlova**  
**Transhare Corporation**  
**Bayside Center 1**  
**17755 US Highway 19 N**  
**Suite 140**  
**Clearwater FL 33764**

**IMPORTANT:** For this Proxy to be valid, the duly completed and signed Proxy must be received on or before 10:00 a.m. Beijing Time on July 1, 2023 or 48 hours before any adjourned time and date of the Meeting.

Please date this Proxy and sign exactly as your name or names appear hereon. If shares are held jointly, both owners must sign. In the case of a shareholder that is not a natural person, this proxy card must be executed by a duly authorized officer or attorney of such entity. Executors, administrators, trustees, guardians and others signing in a representative capacity should give their full titles.

Signature of Shareholder

---

Signature of Joint Shareholder

---

Dated: